Prospectus

AudioCodes Announces Launch of Public Offering of Ordinary Shares

Tuesday, June 2, 2020 - 11:27am

LOD, Israel, June 2, 2020 /PRNewswire/ --AudioCodes (NASDAQ: AUDC) today announced the launch of an underwritten public offering of 2,600,000 ordinary shares pursuant to a registration statement on Form F-3 filed with the Securities and Exchange Commission ("SEC").

Key Points: 
  • LOD, Israel, June 2, 2020 /PRNewswire/ --AudioCodes (NASDAQ: AUDC) today announced the launch of an underwritten public offering of 2,600,000 ordinary shares pursuant to a registration statement on Form F-3 filed with the Securities and Exchange Commission ("SEC").
  • AudioCodes expects to grant the underwriters a 30-day option to purchase up to an additional 390,000 ordinary shares.
  • AudioCodes intends to use the proceeds from the offering for general corporate purposes, including, among other things, working capital requirements and possible future acquisitions.
  • AudioCodes has filed a preliminary prospectus supplement to its shelf registration statement on Form F-3 with the SEC for the proposed offering of its ordinary shares.

BioCryst Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Completion of Public Offering of Common Stock and Pre-Funded Warrants

Monday, June 1, 2020 - 9:01pm

RESEARCH TRIANGLE PARK, N.C., June 01, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today the completion of an underwritten public offering of 22,044,447 shares of its common stock, including 3,333,334 shares sold pursuant to the exercise in full of the underwriters option to purchase additional shares, and of pre-funded warrants to purchase up to an aggregate of 3,511,111 shares of common stock.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., June 01, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today the completion of an underwritten public offering of 22,044,447 shares of its common stock, including 3,333,334 shares sold pursuant to the exercise in full of the underwriters option to purchase additional shares, and of pre-funded warrants to purchase up to an aggregate of 3,511,111 shares of common stock.
  • The gross proceeds from this offering to BioCryst, including from the shares sold pursuant to the underwriters option to purchase additional shares, were approximately $115 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by BioCryst.
  • J.P. Morgan and Piper Sandler acted as joint book-running managers for the offering.
  • A prospectus supplement relating to the offering has been filed with the SEC and is available on its website at www.sec.gov.

China Jo-Jo Drugstores Announces $10 Million Registered Direct Offering

Monday, June 1, 2020 - 2:25pm

Jo-Jo Drugstores also agreed to issue to the investors unregistered warrants to purchase up to 3,750,003 shares of common stock.

Key Points: 
  • Jo-Jo Drugstores also agreed to issue to the investors unregistered warrants to purchase up to 3,750,003 shares of common stock.
  • China Jo-JoDrugstores intends to use the net proceeds from the offering for general corporate purposes and working capital.
  • When filed with the SEC, copies of the final prospectus supplement and the accompanying prospectus relating to the registered direct offering may be obtained at the SEC's website at http://www.sec.gov .
  • China Jo-Jo Drugstores, Inc. ("Jo-Jo Drugstores" or the "Company"), is a leading online and offline retailer and wholesale distributor of pharmaceutical and other healthcare products and a provider of healthcare services inChina.

ARCA Biopharma Announces $9.4 Million Registered Direct Offering

Monday, June 1, 2020 - 1:20pm

The gross proceeds to ARCA, before deducting placement agent fees and other offering expenses, are expected to be approximately $9.4 million.

Key Points: 
  • The gross proceeds to ARCA, before deducting placement agent fees and other offering expenses, are expected to be approximately $9.4 million.
  • ARCA anticipates that the net proceeds from this offering will be used to initiate its clinical trial of AB201 and for working capital and general corporate purposes.
  • A prospectus supplement and the accompanying prospectus relating to the registered direct offering will be filed with the SEC.
  • ARCA biopharma is dedicated to developing genetically targeted therapies for cardiovascular diseases through a precision medicine approach to drug development.

Calliditas Therapeutics Launches US IPO Roadshow and Targets a Capital Raise of MUSD 75

Monday, June 1, 2020 - 12:25pm

The target size of the global offering is MUSD 75 of gross proceeds plus a potential over-allotment of 15 percent.

Key Points: 
  • The target size of the global offering is MUSD 75 of gross proceeds plus a potential over-allotment of 15 percent.
  • An application to list the American Depositary Shares ("ADSs") on The Nasdaq Global Market, under the symbol "CALT", has been submitted.
  • Calliditas' common shares are currently listed on Nasdaq Stockholm under the symbol "CALTX" and Calliditas intends to maintain the listing on Nasdaq Stockholm.
  • The filing of the preliminary prospectus in the United States with the SEC has no implications for Calliditas' listing on Nasdaq Stockholm in Sweden.

Calliditas Therapeutics Launches US IPO Roadshow and Targets a Capital Raise of MUSD 75

Monday, June 1, 2020 - 12:23pm

The target size of the global offering is MUSD 75 of gross proceeds plus a potential over-allotment of 15 percent.

Key Points: 
  • The target size of the global offering is MUSD 75 of gross proceeds plus a potential over-allotment of 15 percent.
  • An application to list the American Depositary Shares ("ADSs") on The Nasdaq Global Market, under the symbol "CALT", has been submitted.
  • Calliditas' common shares are currently listed on Nasdaq Stockholm under the symbol "CALTX" and Calliditas intends to maintain the listing on Nasdaq Stockholm.
  • The filing of the preliminary prospectus in the United States with the SEC has no implications for Calliditas' listing on Nasdaq Stockholm in Sweden.

MESA AIR 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Mesa Air Group, Inc. - MESA

Saturday, May 30, 2020 - 3:50am

This action is pending in the United States District Court for the District of Arizona.

Key Points: 
  • This action is pending in the United States District Court for the District of Arizona.
  • Mesa and certain of its executives are charged with failing to disclose material information in its IPO Registration Statement and Prospectus, violating federal securities laws.
  • The case is Lowthorp v. Mesa Air Group Incorporated, et al, 20-cv-648.
  • About Kahn Swick & Foti, LLC
    KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nations premier boutique securities litigation law firms.

Innovative Industrial Properties Announces Exercise of Option to Purchase Additional Shares of Common Stock

Friday, May 29, 2020 - 9:25pm

Innovative Industrial Properties, Inc. (the Company) (NYSE: IIPR) announced today the full exercise of the underwriters option to purchase an additional 202,259 shares of common stock in connection with the Companys previously announced follow-on offering that priced on May 26, 2020.

Key Points: 
  • Innovative Industrial Properties, Inc. (the Company) (NYSE: IIPR) announced today the full exercise of the underwriters option to purchase an additional 202,259 shares of common stock in connection with the Companys previously announced follow-on offering that priced on May 26, 2020.
  • In total, the Company sold 1,550,648 shares of common stock in the offering, raising gross offering proceeds of approximately $115.0 million.
  • The offering of the Companys common stock is being made only by means of a prospectus supplement and the accompanying prospectus.
  • Innovative Industrial Properties, Inc. has elected to be taxed as a REIT, commencing with the year ended December 31, 2017.

Pricing of Secondary Offering

Friday, May 29, 2020 - 2:37pm

Pan American will pay the Underwriters a cash commission equal to 4.0% of the gross proceeds of the Secondary Offering, including proceeds received from the exercise of the Over-Allotment Option, at the closing of the Secondary Offering.

Key Points: 
  • Pan American will pay the Underwriters a cash commission equal to 4.0% of the gross proceeds of the Secondary Offering, including proceeds received from the exercise of the Over-Allotment Option, at the closing of the Secondary Offering.
  • The Secondary Offering has not been approved or disapproved by any regulatory authority, nor has any such authority passed on the accuracy or adequacy of the prospectus supplement.
  • The Secondary Offering is expected to close on or about June 5, 2020.
  • As previously announced, Pan American has notified Maverix of its intention to exercise 8,250,000 common share purchase warrants (the Warrants) on closing of the Secondary Offering.

Tetraphase Announces Second Amendment to Merger Agreement with AcelRx Pharmaceuticals for Increased Consideration

Friday, May 29, 2020 - 1:43pm

The boards of directors of Tetraphase and AcelRx have each approved the second amendment to the Merger Agreement.

Key Points: 
  • The boards of directors of Tetraphase and AcelRx have each approved the second amendment to the Merger Agreement.
  • Tetraphases board of directors has determined that as a result of the second amendment to the Merger Agreement with AcelRx, Melintas proposal is not superior and recommends the Merger Agreement, as amended by the amendment, to its stockholders.
  • In connection with the proposed transaction between Tetraphase and AcelRx, AcelRx filed with the Securities and Exchange Commission (the SEC) the Registration Statement containing a document constituting a prospectus of AcelRx and a proxy statement of Tetraphase.
  • Tetraphase and its directors and executive officers may be deemed to be participants in the solicitation of proxies from Tetraphase stockholders in respect of the transactions contemplated by the AcelRx Merger Agreement.